Tables [1](T1), [2](T2) and [3](T3) show the top 10 drugs for the year July 2018 -- June 2019. The figures are based on PBS and RPBS prescriptions from the date of supply. The figures include prescriptions under the co-payment (non-subsidised).

###### Top 10 PBS/RPBS drugs by DDD/1000 population/day

  Drug               DDD/1000 pop/day\*
  ------------------ --------------------
  1\. atorvastatin   71 .35
  2\. rosuvastatin   57.44
  3\. perindopril    51 .67
  4\. amlodipine     47.95
  5\. candesartan    32.90
  6\. irbesartan     31.48
  7\. telmisartan    31.26
  8\. esomeprazole   27.62
  9\. ramipril       26.97
  10\. metformin     25.1 4

DDD defined daily dose

PBS Pharmaceutical Benefits Scheme

RPBS Repatriation Pharmaceutical Benefits Scheme

\* DDD/1000 population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calculation is based on ABS 3101.0 -- Australian Demographic Statistics for December 2018.

###### Top 10 PBS/RPBS drugs by prescription counts

  Drug                                Prescriptions
  ----------------------------------- ---------------
  1\. rosuvastatin                    12,026,655
  2\. atorvastatin                    10,967,105
  3\. esomeprazole                    9,278,125
  4\. pantoprazole                    7,375,606
  5\. perindopril                     6,551 ,5 7 1
  6\. cefalexin                       5,643,287
  7\. amoxicillin                     5,254,8 1 1
  8\. metformin                       5,01 7,700
  9\. amoxicillin + clavulanic acid   4,706,645
  10\. escitalopram                   4,533,725

###### Top 10 PBS/RPBS drugs by cost to government (does not include rebates)

  Drug                              Cost to government   DDD/1000 pop/day\*   Prescriptions
  --------------------------------- -------------------- -------------------- ---------------
  1\. sofosbuvir + velpatasvir†     \$391,007,833        ‡                    25,447
  2\. aflibercept\*                 \$358,636,7 2 1      ‡                    289,522
  3\. adalimumab                    \$3 17,436,1 7 5     0.74                 246,220
  4\. nivolumab\*                   \$267,738,344        ‡                    53,861
  5\. pembrolizumab\*               \$220,469,394        ‡                    25,676
  6\. denosumab                     \$218,970,1 1 8      16.80                786,535
  7\. ranibizumab\*                 \$207,163,441        ‡                    180,7 2 1
  8\. ustekinumab                   \$178,790,589        0.44                 25,7 3 1
  9\. glecaprevir + pibrentasvir†   \$173,610,672        ‡                    9,207
  10\. apixaban                     \$170,049,35 1       5.55                 2,088,604

† DDDs for combination products are accounted for in constituent drugs

‡ The World Health Organization has not allocated a DDD for this drug
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